Literature DB >> 10406310

Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force.

L R Armstrong1, C S Derkay, W C Reeves.   

Abstract

OBJECTIVE: To characterize the spectrum of juvenile-onset recurrent respiratory papillomatosis (RRP) in the United States and to obtain data about the natural course of the disease and its response to treatment.
SETTING: Twenty tertiary-care pediatric otolaryngology centers throughout the United States. PATIENTS: All patients with active RRP aged less than 18 years at the participating sites. MAIN OUTCOME MEASURES: Number of surgical procedures performed per year, progression of papillomas to previously nondiseased anatomical sites, drug interventions and other adjuvant therapy, and need for tracheostomy.
RESULTS: Data were collected from 399 children enrolled from January, 1, 1997, through December 31, 1998. There were 51.9% male; 62.7% white, 28.3% black, 9.0% other or unknown racial group; 10.8% Hispanic ethnicity. Mean age at diagnosis was 3.8 years (range, 0.1-16.3 years) and mean duration of disease was 4.4 years (range, 0.03-18.9 years). The mean number of surgical procedures per child was 4.4 per year (range, 0.2-19.3 per year). Children whose RRP was diagnosed at younger ages (<3.0 years) were 3.6 times more likely to have more than 4 surgical procedures per year (P=.001) and almost 2 times more likely to have 2 or more anatomical sites affected (P=.008) than were children whose RRP was diagnosed at later ages (> or =3.0 years), after adjusting for sex, race, and years of treatment.
CONCLUSIONS: Children whose disease was diagnosed before age 3 years were more likely than children aged 3 years or older to have more severe disease as measured by the mean number of surgical procedures performed and by the number of anatomical sites affected. The registry will form the basis for future analysis on the outcome of disease, natural course of RRP under management strategies, prevention strategies, and public health importance.

Entities:  

Mesh:

Year:  1999        PMID: 10406310     DOI: 10.1001/archotol.125.7.743

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  37 in total

1.  Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis.

Authors:  Magdalena Chirilă; Sorana D Bolboacă
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05       Impact factor: 2.503

2.  Intralesional Cidofovir application in recurrent laryngeal papillomatosis.

Authors:  Annett Pudszuhn; Cornelia Welzel; Marc Bloching; Kerstin Neumann
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-10-13       Impact factor: 2.503

3.  Office-based Management of Recurrent Respiratory Papilloma.

Authors:  Kevin M Motz; Alexander T Hillel
Journal:  Curr Otorhinolaryngol Rep       Date:  2016-03-31

4.  Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis.

Authors:  Scott B Drutman; Filomeen Haerynck; Franklin L Zhong; David Hum; Nicholas J Hernandez; Serkan Belkaya; Franck Rapaport; Sarah Jill de Jong; David Creytens; Simon J Tavernier; Katrien Bonte; Sofie De Schepper; Jutte van der Werff Ten Bosch; Lazaro Lorenzo-Diaz; Andy Wullaert; Xavier Bossuyt; Gérard Orth; Vincent R Bonagura; Vivien Béziat; Laurent Abel; Emmanuelle Jouanguy; Bruno Reversade; Jean-Laurent Casanova
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

5.  Malignant conversion of a solitary squamous cell papilloma in the trachea treated by radiotherapy: A case report.

Authors:  Gang Feng; Dong Wang; L I Chen; Gang Xie; Y U Zhang; Jing Wang; Xiao-Bo DU
Journal:  Oncol Lett       Date:  2015-03-20       Impact factor: 2.967

Review 6.  Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis.

Authors:  Vivien Béziat
Journal:  Hum Genet       Date:  2020-05-20       Impact factor: 4.132

7.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503

8.  Multicenter initiative seeking critical genes in respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Craig S Derkay; Suzanne M Leal; Joseph Donfack; Garth D Ehrlich; J Christopher Post
Journal:  Laryngoscope       Date:  2004-02       Impact factor: 3.325

Review 9.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

Review 10.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.